BioSpace News Archive

Jazz Pharmaceuticals exercised its option on Zymeworks’ promising anti-cancer agent.

2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications.

The U.S. Department of Justice indicted former CytoDyn Inc. CEO Nader Z. Pourhassan and the CEO of Amarex Clinical Research on multiple counts of fraud.

Dxcover Limited, a clinical stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, announced that it has been awarded a grant from the European Innovation Council through its Accelerator program.

Viridian Therapeutics, Inc. today announced that the first patient has been enrolled in its THRIVE Phase 3 trial evaluating the efficacy and safety of the investigational agent VRDN-001 in patients with active thyroid eye disease (TED).

CytoSorbents Corporation announced that it has received the recommendation from the independent Data and Safety Monitoring Board to continue the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) trial as planned without any modifications.

Dr. Eric Gulve has announced his retirement from BioSTL after 15 years as President of its startup arm, BioGenerator , and as Executive Vice President of BioSTL.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma, a rare but potentially fatal cancer with no FDA-approved therapy.

AEON Biopharma, Inc. today announced the completion of patient enrollment in the Phase 2 study of ABP-450 for the preventive treatment of episodic migraine.

KemPharm, Inc. today announced the initiation of a Phase 2 clinical trial evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder.